Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 181

1.

Glucocerebrosidase is shaking up the synucleinopathies.

Siebert M, Sidransky E, Westbroek W.

Brain. 2014 May;137(Pt 5):1304-22. doi: 10.1093/brain/awu002. Epub 2014 Feb 14. Review.

2.

Gaucher-related synucleinopathies: the examination of sporadic neurodegeneration from a rare (disease) angle.

Sardi SP, Cheng SH, Shihabuddin LS.

Prog Neurobiol. 2015 Feb;125:47-62. doi: 10.1016/j.pneurobio.2014.12.001. Epub 2015 Jan 6. Review.

3.

Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation.

Fishbein I, Kuo YM, Giasson BI, Nussbaum RL.

Brain. 2014 Dec;137(Pt 12):3235-47. doi: 10.1093/brain/awu291. Epub 2014 Oct 27.

4.

Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.

McNeill A, Magalhaes J, Shen C, Chau KY, Hughes D, Mehta A, Foltynie T, Cooper JM, Abramov AY, Gegg M, Schapira AH.

Brain. 2014 May;137(Pt 5):1481-95. doi: 10.1093/brain/awu020. Epub 2014 Feb 25.

5.

Gaucher disease and the synucleinopathies: refining the relationship.

Campbell TN, Choy FY.

Orphanet J Rare Dis. 2012 Jan 31;7:12. doi: 10.1186/1750-1172-7-12. Review.

6.

A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism.

Aflaki E, Borger DK, Moaven N, Stubblefield BK, Rogers SA, Patnaik S, Schoenen FJ, Westbroek W, Zheng W, Sullivan P, Fujiwara H, Sidhu R, Khaliq ZM, Lopez GJ, Goldstein DS, Ory DS, Marugan J, Sidransky E.

J Neurosci. 2016 Jul 13;36(28):7441-52. doi: 10.1523/JNEUROSCI.0636-16.2016.

7.

Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond.

Shachar T, Lo Bianco C, Recchia A, Wiessner C, Raas-Rothschild A, Futerman AH.

Mov Disord. 2011 Aug 1;26(9):1593-604. doi: 10.1002/mds.23774. Epub 2011 May 26. Review.

PMID:
21618611
8.

Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease.

Jung O, Patnaik S, Marugan J, Sidransky E, Westbroek W.

Expert Rev Proteomics. 2016 May;13(5):471-9. doi: 10.1080/14789450.2016.1174583. Epub 2016 Apr 21. Review.

9.

The Complicated Relationship between Gaucher Disease and Parkinsonism: Insights from a Rare Disease.

Aflaki E, Westbroek W, Sidransky E.

Neuron. 2017 Feb 22;93(4):737-746. doi: 10.1016/j.neuron.2017.01.018. Review.

PMID:
28231462
10.

Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.

Blanz J, Saftig P.

J Neurochem. 2016 Oct;139 Suppl 1:198-215. doi: 10.1111/jnc.13517. Epub 2016 Feb 10. Review.

11.

Hypercoagulability, parkinsonism, and Gaucher disease.

Rosenbaum H, Aharon-Peretz J, Brenner B.

Semin Thromb Hemost. 2013 Nov;39(8):928-34. doi: 10.1055/s-0033-1357485. Epub 2013 Oct 15. Review.

PMID:
24129683
12.

Gaucher disease: complexity in a "simple" disorder.

Sidransky E.

Mol Genet Metab. 2004 Sep-Oct;83(1-2):6-15. Review.

PMID:
15464415
13.

Development of targeted therapies for Parkinson's disease and related synucleinopathies.

Sybertz E, Krainc D.

J Lipid Res. 2014 Oct;55(10):1996-2003. doi: 10.1194/jlr.R047381. Epub 2014 Mar 25. Review.

14.

[Gaucher disease: clinical, genetic and therapeutic aspects].

Germain DP.

Pathol Biol (Paris). 2004 Jul;52(6):343-50. Review. French.

PMID:
15261378
15.

Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease.

Wong YC, Krainc D.

Mov Disord. 2016 Nov;31(11):1610-1618. doi: 10.1002/mds.26802. Epub 2016 Sep 13. Review.

PMID:
27619775
16.

Neuroinflammation and α-synuclein accumulation in response to glucocerebrosidase deficiency are accompanied by synaptic dysfunction.

Ginns EI, Mak SK, Ko N, Karlgren J, Akbarian S, Chou VP, Guo Y, Lim A, Samuelsson S, LaMarca ML, Vazquez-DeRose J, Manning-Boğ AB.

Mol Genet Metab. 2014 Feb;111(2):152-62. doi: 10.1016/j.ymgme.2013.12.003. Epub 2013 Dec 11.

PMID:
24388731
17.

Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies.

Sardi SP, Clarke J, Viel C, Chan M, Tamsett TJ, Treleaven CM, Bu J, Sweet L, Passini MA, Dodge JC, Yu WH, Sidman RL, Cheng SH, Shihabuddin LS.

Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3537-42. doi: 10.1073/pnas.1220464110. Epub 2013 Jan 7.

18.

Gaucher disease: a lysosomal neurodegenerative disorder.

Huang WJ, Zhang X, Chen WW.

Eur Rev Med Pharmacol Sci. 2015 Apr;19(7):1219-26. Review.

19.

The emergence of Parkinson disease among patients with Gaucher disease.

Elstein D, Alcalay R, Zimran A.

Best Pract Res Clin Endocrinol Metab. 2015 Mar;29(2):249-59. doi: 10.1016/j.beem.2014.08.007. Epub 2014 Aug 23. Review.

PMID:
25987177
20.

Parkinson's disease in patients and obligate carriers of Gaucher disease.

Becker JG, Pastores GM, Di Rocco A, Ferraris M, Graber JJ, Sathe S.

Parkinsonism Relat Disord. 2013 Jan;19(1):129-31. doi: 10.1016/j.parkreldis.2012.06.023. Epub 2012 Aug 31.

PMID:
22940477

Supplemental Content

Support Center